WOMAN-PharmacoTXA trial: Study protocol for a randomised controlled trial to assess the pharmacokinetics and pharmacodynamics of intramuscular, intravenous and oral administration of tranexamic acid in women giving birth by caesarean section

Monica Arribas, Ian Roberts, Rizwana Chaudhri, Amber Geer, Danielle Prowse, Mwansa Ketty Lubeya, Aasia Kayani, Kiran Javaid, Stanislas Grassin-Delyle, Haleema Shakur-Still, Monica Arribas, Ian Roberts, Rizwana Chaudhri, Amber Geer, Danielle Prowse, Mwansa Ketty Lubeya, Aasia Kayani, Kiran Javaid, Stanislas Grassin-Delyle, Haleema Shakur-Still

Abstract

Background: Intravenous tranexamic acid (TXA) within 3 hours of birth significantly reduces death due to bleeding in women with postpartum haemorrhage (PPH). Most PPH deaths occur in the first hours after giving birth and treatment delay decreases survival. One barrier to rapid TXA treatment is the need for intravenous injection. Intramuscular injection and oral solution of TXA would be easier and faster to administer and would require less training. However, the pharmacokinetics (PK), pharmacodynamics and safety of TXA administered by different routes in pregnant women have not been established. The main aim of this study is to ascertain whether IM and oral solution of TXA will be absorbed at levels sufficient to inhibit fibrinolysis in pregnant women. Methods: WOMAN-PharmacoTXA is a prospective, randomised, open label trial to be conducted in Zambia and Pakistan. Adult women undergoing caesarean section with at least one risk factor for PPH will be included. Women will be randomised to receive one of the following about 1 hour prior to caesarean section: 1-gram TXA IV, 1-gram TXA IM, 4-grams TXA oral solution or no TXA. Randomisation will continue until 120 participants with at least six post randomisation PK samples are included. TXA concentration in maternal blood samples will be measured at baseline and at different time points during 24 hours after receipt of intervention. Blood TXA concentration will be measured from the umbilical cord and neonate. The primary endpoint is maternal blood TXA concentrations over time. Secondary outcomes include umbilical cord and neonate TXA concentration D-dimer concentration, blood loss and clinical diagnosis of PPH, injection site reactions and maternal and neonate adverse events. Discussion: The WOMAN-PharmacoTXA trial will provide important data on pharmacokinetics, pharmacodynamics and safety of TXA after IV, intramuscular and oral administration in women giving birth by caesarean section. Trial registration: ClincalTrials.gov, NCT04274335 (18/02/2020).

Keywords: Antifibrinolytic; PPH; Pharmacodynamics; Pharmacokinetics; Tranexamic acid; caesarean section; clinical trial; intramuscular; oral.

Conflict of interest statement

No competing interests were disclosed.

Copyright: © 2021 Arribas M et al.

Figures

Figure 1.. Trial overview.
Figure 1.. Trial overview.
Figure 2.. Summary of trial procedures.
Figure 2.. Summary of trial procedures.
Figure 3.. Timing of biological samples.
Figure 3.. Timing of biological samples.

References

    1. WHO: Priority diseases and reasons for inclusion. Chapter 6.16 Postpartum haemorrhage.2012.
    1. Calvert C, Thomas SL, Ronsmans C, et al. : Identifying regional variation in the prevalence of postpartum haemorrhage: a systematic review and meta-analysis. PLoS One. 2012;7(7):e41114. 10.1371/journal.pone.0041114
    1. Carroli G, Cuesta C, Abalos E, et al. : Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008;22(6):999–1012. 10.1016/j.bpobgyn.2008.08.004
    1. World Health Organization (WHO), UNICEF, UNFPA, The World Bank: Trends in maternal mortality: 1990 to 2010.2012.
    1. Say L, Chou D, Gemmill A, et al. : Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323–33. 10.1016/S2214-109X(14)70227-X
    1. McCormack PL: Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012;72(5):585–617. 10.2165/11209070-000000000-00000
    1. Cesarman-Maus G, Hajjar KA: Molecular mechanisms of fibrinolysis. Br J Haematol. 2005;129(3):307–21. 10.1111/j.1365-2141.2005.05444.x
    1. WOMAN Trial Collaborators: Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017;389(10084):2105–16. 10.1016/S0140-6736(17)30638-4
    1. Gayet-Ageron A, Prieto-Merino D, Ker K, et al. : Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018;391(10116):125–32. 10.1016/S0140-6736(17)32455-8
    1. Picetti R, Shakur-Still H, Medcalf RL, et al. : What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis. 2019;30(1):1–10. 10.1097/MBC.0000000000000789
    1. Puigdellivol E, Carral ME, Moreno J, et al. : Pharmacokinetics and absolute bioavailability of intramuscular tranexamic acid in man. Int J Clin Pharmacol Ther Toxicol. 1985;23(6):298–301.
    1. Sano M, Hakusui H, Kojima C, et al. : Absorption and Excretion of Tranexamic Acid following Intravenous, Intramuscular and Oral Administrations in Healthy Volunteers. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 1976;7(4):375–82. 10.3999/jscpt.7.375
    1. Grassin-Delyle S, Semeraro M, Foissac F, et al. : Tranexamic acid through intravenous, intramuscular and oral routes: an individual participant data meta-analysis of pharmacokinetic studies in healthy volunteers. Fundam Clin Pharmacol. 2019;33(6):670–8. 10.1111/fcp.12474
    1. Grassin-Delyle S, Shakur-Still H, Picetti R, et al. : Pharmacokinetics of intramuscular tranexamic acid in bleeding trauma patients: a clinical trial. Br J Anaesth. 2021;126(1):201–209. 10.1016/j.bja.2020.07.058
    1. Ducloy-Bouthors AS, Jeanpierre E, Saidi I, et al. : TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial. Trials. 2018;19(1):149. 10.1186/s13063-017-2421-6
    1. Costantine MM: Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014;5:65. 10.3389/fphar.2014.00065
    1. Mavrides E, Allard S, Chandraharan E, et al. : Prevention and Management of Postpartum Haemorrhage. BJOG. 2017;124(5):e106–e49. 10.1111/1471-0528.14178
    1. Leduc D, Senikas V, Lalonde AB, et al. : Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. J Obstet Gynaecol Can. 2009;31(10):980–93. 10.1016/S1701-2163(16)34329-8
    1. Pilbrant A, Schannong M, Vessman J: Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol. 1981;20(1):65–72. 10.1007/BF00554669
    1. Hopkins U, Arias CY: Large-volume IM injections: A review of best practices. Oncology Nurse Advisor.2013.
    1. Sindet-Pedersen S: Distribution of tranexamic acid to plasma and saliva after oral administration and mouth rinsing: a pharmacokinetic study. J Clin Pharmacol. 1987;27(12):1005–8. 10.1002/j.1552-4604.1987.tb05605.x
    1. Moore KA, Morin I, Marenco T, et al. : Pharmacokinetic studies in women of 2 novel oral formulations of tranexamic acid therapy for heavy menstrual bleeding. Am J Ther. 2012;19(3):190–8. 10.1097/MJT.0b013e318205427a
    1. FDA: Lysteda approval package.2004.
    1. FDA Lysteda: Pharmacology/toxicology review and evaluation.2009.
    1. CRASH-2 collaborators, Roberts I, Shakur H, et al. : The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096–101, 1101. e1–2. 10.1016/S0140-6736(11)60278-X
    1. CRASH-2 trial collaborators, Shakur H, Roberts I, et al. : Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23–32. 10.1016/S0140-6736(10)60835-5
    1. Ker K, Edwards P, Perel P, et al. : Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ. 2012;344:e3054. 10.1136/bmj.e3054
    1. Ker K, Prieto-Merino D, Roberts I: Systematic review, meta-analysis and meta-regression of the effect of tranexamic acid on surgical blood loss. Br J Surg. 2013;100(10):1271–9. 10.1002/bjs.9193
    1. Cyklokapron Tablets.2018.
    1. Cyklokapron Injection.2019.
    1. Heit JA, Kobbervig CE, James AH, et al. : Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706. 10.7326/0003-4819-143-10-200511150-00006
    1. Pealing L, Perel P, Prieto-Merino D, et al. : Risk factors for vascular occlusive events and death due to bleeding in trauma patients; an analysis of the CRASH-2 cohort. PLoS One. 2012;7(12):e50603. 10.1371/journal.pone.0050603
    1. Gilad O, Merlob P, Stahl B, et al. : Outcome following tranexamic acid exposure during breastfeeding. Breastfeed Med. 2014;9(8):407–10. 10.1089/bfm.2014.0027
    1. Peitsidis P, Kadir RA: Antifibrinolytic therapy with tranexamic acid in pregnancy and postpartum. Expert Opin Pharmacother. 2011;12(4):503–16. 10.1517/14656566.2011.545818
    1. Verstraete M: Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29(3):236–61. 10.2165/00003495-198529030-00003
    1. Kullander S, Nilsson IM: Human placental transfer of an antifibrinolytic agent (AMCA). Acta Obstet Gynecol Scand. 1970;49(3):241–2. 10.3109/00016347009157244
    1. Walzman M, Bonnar J: Effects of tranexamic acid on the coagulation and fibrinolytic systems in pregnancy complicated by placental bleeding. Arch Toxicol Suppl. 1982;5:214–20. 10.1007/978-3-642-68511-8_39
    1. Andersson L, Nilsson IM, Nilehn JE, et al. : Experimental and clinical studies on AMCA, the antifibrinolytically active isomer of p-aminomethyl cyclohexane carboxylic acid. Scand J Haematol. 1965;2(3):230–47. 10.1111/j.1600-0609.1965.tb01300.x
    1. Gai MY, Wu LF, Su QF, et al. : Clinical observation of blood loss reduced by tranexamic acid during and after caesarian section: a multi-center, randomized trial. Eur J Obstet Gynecol Reprod Biol. 2004;112(2):154–7. 10.1016/s0301-2115(03)00287-2
    1. Topsoee MF, Settnes A, Ottesen B, et al. : A systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery. Int J Gynaecol Obstet. 2017;136(2):120–7. 10.1002/ijgo.12047
    1. Wang Y, Liu S, He L: Prophylactic use of tranexamic acid reduces blood loss and transfusion requirements in patients undergoing cesarean section: A meta-analysis. J Obstet Gynaecol Res. 2019;45(8):1562–75. 10.1111/jog.14013
    1. Ahmadzia HK, Phillips JM, Katler QS, et al. : Tranexamic Acid for Prevention and Treatment of Postpartum Hemorrhage: An Update on Management and Clinical Outcomes. Obstet Gynecol Surv. 2018;73(10):587–94. 10.1097/OGX.0000000000000597
    1. Frimat M, Decambron M, Lebas C, et al. : Renal Cortical Necrosis in Postpartum Hemorrhage: A Case Series. Am J Kidney Dis. 2016;68(1):50–7. 10.1053/j.ajkd.2015.11.022
    1. Li C, Gong Y, Dong L, et al. : Is prophylactic tranexamic acid administration effective and safe for postpartum hemorrhage prevention?: A systematic review and meta-analysis. Medicine (Baltimore). 2017;96(1):e5653. 10.1097/MD.0000000000005653
    1. Pfizer: Cyklokapron.2011.
    1. Melander B, Gliniecki G, Granstrand B, et al. : Biochemistry and toxicology of amikapron; the antifibrinolytically active isomer of AMCHA. (A comparative study with epsilon-aminocaproic acid). Acta Pharmacol Toxicol (Copenh). 1965;22(4):340–52. 10.1111/j.1600-0773.1965.tb01829.x
    1. Morita H, Tachizawa H, Akimoto T: Evaluation of safety of tranexamic acid: teratogenic effects in mice and rats. Oyo Yakuri. 1971;5:415–20.
    1. Chan AW, Tetzlaff JM, Gotzsche PC, et al. : SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. 10.1136/bmj.e7586
    1. Shakur-Still H, Arribas M, Roberts I, et al. : WOMAN-PharmacoTXA Trial: Pharmacokinetics and pharmacodynamics of tranexamic acid in women having caesarean section birth - Extended data. [Data Collection]. London School of Hygiene & Tropical Medicine, London, United Kingdom.2021. 10.17037/DATA.00002164
    1. Lamy E, Runge I, Roberts I, et al. : Tranexamic acid quantification in human whole blood using liquid samples or volumetric absorptive microsampling devices. Bioanalysis. 2020;12(12):835–44. 10.4155/bio-2020-0088
    1. Bazzoli C, Retout S, Mentre F: Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. Comput Methods Programs Biomed. 2010;98(1):55–65. 10.1016/j.cmpb.2009.09.012
    1. Grassin-Delyle S, Theusinger OM, Albrecht R, et al. : Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. Anaesthesia. 2018;73(6):719–729. 10.1111/anae.14184
    1. Kuhn E, Lavielle M: Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49(4):1020–38. 10.1016/j.csda.2004.07.002
    1. Grassin-Delyle S, Couturier R, Abe E, et al. : A practical tranexamic acid dosing scheme based on population pharmacokinetics in children undergoing cardiac surgery. Anesthesiology. 2013;118(4):853–62. 10.1097/ALN.0b013e318283c83a
    1. Gertler R, Gruber M, Grassin-Delyle S, et al. : Pharmacokinetics of tranexamic acid in neonates and infants undergoing cardiac surgery. Br J Clin Pharmacol. 2017;83(8):1745–57. 10.1111/bcp.13274
    1. Grassin-Delyle S, Tremey B, Abe E, et al. : Population pharmacokinetics of tranexamic acid in adults undergoing cardiac surgery with cardiopulmonary bypass. Br J Anaesth. 2013;111(6):916–24. 10.1093/bja/aet255
    1. : Optimal use of intravenous tranexamic acid for hemorrhage prevention in pregnant women. Am J Obstet Gynecol .2020; 10.1016/j.ajog.2020.11.035 10.1016/j.ajog.2020.11.035
    1. : Population pharmacokinetics and pharmacodynamics of Tranexamic acid in women undergoing caesarean delivery. Br J Clin Pharmacol .2021; 10.1111/bcp.14767 10.1111/bcp.14767
    1. : Application of a plasmin generation assay to define pharmacodynamic effects of tranexamic acid in women undergoing cesarean delivery. J Thromb Haemost .19(1) : 10.1111/jth.15114 221-232 10.1111/jth.15114
    1. : Tranexamic Acid for the Prevention of Blood Loss after Cesarean Delivery. New England Journal of Medicine .2021;384(17) : 10.1056/NEJMoa2028788 1623-1634 10.1056/NEJMoa2028788

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever